about
Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future ConsiderationsHigh clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).Clinical characteristics and prognosis of primary pancreatic carcinoid tumors: A report of 13 cases from a single institution.Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.Bilateral Choroidal Metastases from Endobronchial Carcinoid Treated with Somatostatin Analogues.Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem.Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.Targeting PI3K/Akt/mTOR Signaling in Cancer.Primary neuroendocrine tumor (carcinoid tumor) of the testis: a case report with review of literaturePeptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms.Midgut neuroendocrine tumor presenting with acute intestinal ischemia.Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies.
P2860
Q28084155-39969549-4516-40A7-8D04-B86809AD6C36Q33435622-3EC0A50A-91AD-4AC3-9DBE-4A33A753D894Q34157391-B579A54A-69DF-41CE-A4B5-D650D4DEF02EQ34993771-0D953383-2C15-4201-AC6E-287AE8412F80Q36072479-1ADE6274-5128-4CFB-B1B5-78EA50CA96CEQ36192331-F6817256-3128-43C0-9AD9-FF1E8FD43BB8Q37310556-11714D73-A457-4C95-A986-53954B017FF7Q37520405-90316424-8882-4B2F-ABB2-30A55B7E521CQ38208314-E3BF7698-59F2-4640-B802-51F8AC5DA98CQ38508958-184EE763-5EE5-4E50-BB57-A3A028FC4C23Q41244010-516F3802-2C45-4609-894A-80D55BFFF88AQ41496806-F9DC7FEE-D652-4688-8908-EC3283AC6139Q47134839-A82B38D3-2D17-4770-8F73-37DBE45ED6ADQ47632942-E8A6C963-B210-4D8C-A3F9-966280D1D4AD
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Systemic therapeutic options for carcinoid.
@en
type
label
Systemic therapeutic options for carcinoid.
@en
prefLabel
Systemic therapeutic options for carcinoid.
@en
P2093
P1433
P1476
Systemic therapeutic options for carcinoid.
@en
P2093
Irvin Modlin
Marianne Pavel
P356
10.1053/J.SEMINONCOL.2012.11.003
P577
2013-02-01T00:00:00Z